Back to home
CLINICAL SIGNALMarch 20, 2026·6 min read
Moderna-Merck mRNA Cancer Vaccine Shows Durable Melanoma Responses
The personalized mRNA cancer vaccine mRNA-4157 combined with Keytruda continues to show improved recurrence-free survival in high-risk melanoma. mRNA oncology is no longer theoretical.
The full analysis is published in the weekly biotech.today newsletter — subscribe for free to get the next issue in your inbox.